Rigel Pharmaceuticals earnings were $321.9M for the trailing 12 months ending Jun 30, 2026, with 224.8% growth year over year. The latest RIGL earnings report on Jun 30, 2026 announced Q2 2026 earnings of $17.3M, up 99.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, RIGL reported annual earnings of $367.0M, with 1,999.1% growth.
RIGL past earnings growth
How has RIGL's earnings growth performed historically?
Rigel Pharmaceuticals Earnings Reports & History FAQ
What were Rigel Pharmaceuticals's earnings last quarter?
On RIGL's earnings call on Aug 4, 2026, Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 2026 earnings per share (EPS) of $0.93, up 72.07% year over year. Total RIGL earnings for the quarter were $17.29 million. In the same quarter last year, Rigel Pharmaceuticals's earnings per share (EPS) was $3.33.
Is Rigel Pharmaceuticals profitable or losing money?
As of the last Rigel Pharmaceuticals earnings report, Rigel Pharmaceuticals is currently profitable. Rigel Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $321.91 million, a 229.08% increase year over year.
What was RIGL's earnings growth in the past year?
As of Rigel Pharmaceuticals's earnings date in Aug 4, 2026, Rigel Pharmaceuticals's earnings has grown 224.77% year over year. This is 207.58 percentage points higher than the US Biotechnology industry earnings growth rate of 17.19%. RIGL earnings in the past year totalled $321.91 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.